))
In the Clinic: Triple Combination CFTR Modulation
Manage episode 288636709 series 2902538
Content provided by eCysticFibrosis Review and ECysticFibrosis Review. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by eCysticFibrosis Review and ECysticFibrosis Review or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Elexacaftor/tezacaftor/ivacaftor — the newly approved triple combination CFTR modulator therapy. What are the benefits? For which patients? What are the potential adverse effects? Who’s most likely to receive them?
In this issue, Dr. Scott Sagel from the Breathing Institute at the Children’s Hospital Colorado, part of the University of Colorado’s Anschutz Medical Campus, takes us to the clinic to discuss some answers.
Take our post-test to claim CME credits.
To read a companion newsletter click here.
Hosted on Acast. See acast.com/privacy for more information.
72 episodes
Share
